 <h1>Foscarnet Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to foscarnet: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Renal impairment is the major toxicity of foscarnet. Frequent monitoring of serum creatinine, with dose adjustment for changes in renal function, and adequate hydration with administration of foscarnet is imperative. Seizures, related to alteration in plasma minerals and electrolytes, have been associated with foscarnet treatment. Therefore, patients must be carefully monitored for such changes and their potential sequelae. Mineral and electrolyte supplementation may be required. Foscarnet is indicated for use only in immunocompromised patients with cytomegalovirus retinitis and mucocutaneous acyclovir-resistant herpes simplex virus infections.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, foscarnet may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking foscarnet:</p><p>
<i>More common</i>
</p><ul>
<li>Increased or decreased frequency of urination or amount of urine</li>
<li>increased thirst</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chills</li>
<li>convulsions</li>
<li>fever</li>
<li>muscle twitching</li>
<li>pain at the injection site </li>
<li>pain or numbness in hands or feet</li>
<li>tingling sensation around the mouth</li>
<li>tremor</li>
<li>unusual tiredness and weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Sores or ulcers on the mouth or throat, penis, or vulva</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Difficulty with breathing or swallowing</li>
<li>fainting</li>
<li>hives or welts, itching, or skin rash</li>
<li>irregular heartbeat recurrent</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>nausea</li>
<li>reddening of the skin, especially around the ears</li>
<li>swelling of the eyes, face, or inside of the nose</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of foscarnet may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>anxious feeling</li>
<li>confusion</li>
<li>dizziness</li>
<li>headache</li>
<li>loss of appetite</li>
<li>nausea and vomiting</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to foscarnet: intravenous solution</i></p><h3>General</h3><p>Renal impairment was the major toxicity of this drug.  The most frequent side effects reported during clinical trials included fever, nausea, anemia, diarrhea, abnormal renal function, vomiting, headache, and seizures.  Severe side effects included death, abnormal renal function, bone marrow suppression, anemia, and seizures.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Renal impairment (up to 33%), abnormal renal function (up to 27%), increased serum creatinine</p>
<p><b>Common</b> (1% to 10%): Altered renal function, decreased CrCl, increased BUN, acute renal failure, renal pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Renal tubular disorder</p>
<p><b>Frequency not reported</b>: Increased serum creatinine to greater than 2.9 mg/dL, acute tubular necrosis, drug crystals in renal tubules and capillaries, nephrotoxicity</p>
<p><b>Postmarketing reports</b>: Nephrogenic diabetes insipidus, renal tubular acidosis, renal calculus, renal tubular necrosis, crystal-induced nephropathy<sup>[Ref]</sup></p><p>About 33% of AIDS patients with CMV retinitis who used this drug without adequate hydration reported significant renal impairment (serum creatinine at least 2 mg/dL).  When administered with 1000 mL of normal saline or 5% dextrose solution, the incidence decreased to 12%.</p>
<p></p>
<p>Renal side effects were due to acute tubular necrosis, possibly from deposition of drug crystals in the renal tubules and capillaries.  The development of nephrotoxicity was most common during the third week of therapy in 1 study.</p>
<p></p>
<p>Nephrotoxicity was reversible in patients with previously adequate renal function.  Hydration with 2.5 liters of normal saline per day beginning the day before therapy decreased the incidence of nephrotoxicity.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Serum electrolyte changes, mineral and electrolyte imbalances, hypokalemia (up to 48%), hypocalcemia (up to 30%), hypomagnesemia (up to 30%), hypophosphatemia (up to 26%), decreased appetite, anorexia</p>
<p><b>Common</b> (1% to 10%): Hyperphosphatemia, abnormal albumin to globulin ratio, hyponatremia, decreased weight, increased alkaline phosphatase, increased lactate dehydrogenase, acidosis, cachexia, thirst</p>
<p><b>Uncommon</b> (0.1% to 1%): Dehydration, hypoproteinemia</p>
<p><b>Frequency not reported</b>: Hypercalcemia., decreased serum ionized calcium levels<sup>[Ref]</sup></p><p>The higher percentages of serum electrolyte changes (including hypokalemia, hypocalcemia, hypomagnesemia, hypophosphatemia, hyperphosphatemia) were reported in patients receiving hydration.</p>
<p></p>
<p>Serum ionized calcium levels have been shown to decrease acutely in a dose-dependent manner after an infusion of this drug.  Total calcium and phosphate levels were not significantly affected.  This drug is believed to complex with ionized calcium.</p>
<p></p>
<p>More severe metabolic abnormalities have resulted in tremors, twitches, arrhythmias, paresthesias, and seizures.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 47%), diarrhea (up to 30%), vomiting (up to 26%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, constipation, dysphagia, dyspepsia, rectal hemorrhage, dry mouth, melena, flatulence, ulcerative stomatitis, pancreatitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased amylase</p>
<p><b>Frequency not reported</b>: Uvula ulceration</p>
<p><b>Postmarketing reports</b>: Esophageal ulceration<sup>[Ref]</sup></p><h3>Other</h3><p>In controlled trials, death was specifically attributed to this drug in 1 case; however, other drug complications (e.g., renal impairment, electrolyte abnormalities, seizures) may have contributed to patient deaths.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Fever/pyrexia (up to 65%), death (up to 14%), fatigue, asthenia, chills</p>
<p><b>Common</b> (1% to 10%): Rigors, malaise, pain, infection, sepsis, chest pain, edema, influenza-like symptoms, bacterial infections, moniliasis, fungal infections, abscess, facial edema</p>
<p><b>Frequency not reported</b>: Catheterization-related infection, hospitalization, drug accumulation in teeth and bones<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (up to 33%), granulocytopenia (up to 17%), decreased hemoglobin</p>
<p><b>Common</b> (1% to 10%): Marrow suppression, neutropenia, leukopenia, thrombocytopenia, platelet abnormalities, thrombosis, white blood cell abnormalities, lymphadenopathy</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancytopenia</p>
<p><b>Frequency not reported</b>: Decreased absolute neutrophil count (ANC) to less than 0.5 x 10(9)/L, hemoglobin less than 7 g/dL<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 26%), paresthesia, dizziness</p>
<p><b>Common</b> (1% to 10%): Seizures/convulsion (including grand mal seizures), involuntary muscle contractions, hypoesthesia, neuropathy, tremor, ataxia, dementia, stupor, generalized spasms, sensory disturbances, meningitis, aphasia, abnormal coordination, leg cramps, electroencephalogram abnormalities, amnesia, somnolence, taste perversions, peripheral neuropathy</p>
<p><b>Uncommon</b> (0.1% to 1%): Coma, other neurologic complications</p>
<p><b>Postmarketing reports</b>: Encephalopathy<sup>[Ref]</sup></p><p>Risk factors for drug-related seizures included underlying central nervous system conditions predisposing patients to seizures, impaired baseline renal function, and low total serum calcium.  The rate of seizures did not increase with duration of therapy.  At least 3 cases were reported with overdoses of this drug.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash</p>
<p><b>Common</b> (1% to 10%): Increased sweating, pruritus, skin ulceration, seborrhea, erythematous rash, maculopapular rash, skin discoloration</p>
<p><b>Frequency not reported</b>: Eosinophilic folliculitis</p>
<p><b>Postmarketing reports</b>: Vesiculobullous eruptions, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome<sup>[Ref]</sup></p><p>When toxic epidermal necrolysis or Stevens-Johnson syndrome was reported, patients were usually taking other agents associated with those reactions.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site pain, injection site inflammation<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, palpitations, ECG abnormalities, sinus tachycardia, first degree atrioventricular block, nonspecific ST-T segment changes, hypotension, flushing, cerebrovascular disorder, thrombophlebitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Cardiac arrest, other cardiovascular complications</p>
<p><b>Frequency not reported</b>: Reversible cardiac dysfunction, increased heart rate</p>
<p><b>Postmarketing reports</b>: Ventricular arrhythmia, QT interval prolongation<sup>[Ref]</sup></p><p>Reversible cardiac dysfunction was reported in a patient using this drug, who experienced shortness of breath, increased heart rate, and pulmonary edema, which reoccurred upon rechallenge.  Serum electrolytes were within normal limits.</p>
<p></p>
<p>Thrombophlebitis in peripheral veins has been reported after infusion of undiluted drug solution.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal hepatic function, increased ALT/SGPT, increased AST/SGOT, increased GGT<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, myalgia</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased creatine phosphokinase</p>
<p><b>Frequency not reported</b>: Twitches</p>
<p><b>Postmarketing reports</b>: Muscle disorders including myopathy, myositis, muscle weakness, rhabdomyolysis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Lymphoma-like disorder, sarcoma<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Coughing, dyspnea, pneumonia, sinusitis, pharyngitis, rhinitis, respiratory disorders, respiratory insufficiency, pulmonary infiltration, stridor, pneumothorax, hemoptysis, bronchospasm</p>
<p><b>Frequency not reported</b>: Pulmonary edema<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, confusion, anxiety, insomnia, nervousness, agitation, aggression, hallucination</p>
<p><b>Postmarketing reports</b>: Mental status changes<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Vision abnormalities, eye abnormalities, eye pain, conjunctivitis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>High levels of this drug are excreted in the urine and may be associated with significant irritation and ulceration in the genital area, especially after prolonged therapy.</p>
<p></p>
<p>Penile ulcerations have been reported to occur after a median of 11 days of induction therapy and 30 days of maintenance therapy, and healed within 6 days of drug discontinuation.  Ulceration has been reported more often in uncircumcised patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Albuminuria, dysuria, polyuria, urethral disorder, urinary retention, urinary tract infections, nocturia, genital discomfort/irritation and ulceration</p>
<p><b>Uncommon</b> (0.1% to 1%): Hematuria</p>
<p><b>Frequency not reported</b>: Local irritation/ulceration of penile epithelium, vulvovaginal ulceration, penile ulceration, vulvar erosion<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Syndrome of inappropriate antidiuretic hormone secretion</p>
<p><b>Postmarketing reports</b>: Diabetes insipidus</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Takami A,  Mochizuki K,  Ito S, et al. "Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation." Transplant Proc 39 (2007): 237-9</p><p id="ref_4">4. "Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA. </p><p id="ref_5">5. Farese RV Jr, Schambelan M, Hollander H, et al "Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis." Ann Intern Med 112 (1990): 955-6</p><p id="ref_6">6. Zanetta G, MauriceEstepa L, Mousson C, Justrabo E, Daudon M, Rifle G, Tanter Y "Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation." Transplantation 67 (1999): 1376-8</p><p id="ref_7">7. Navarro JF, Quereda C, Quereda C, Gallego N, Antela A, Mora C, Ortuno J "Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy." Am J Kidney Dis 27 (1996): 431-4</p><p id="ref_8">8. Deray G, Le Hoang P, Soubrie C, et al "Foscarnet-induced acute renal failure and effectiveness of haemodialysis." Lancet 2 (1987): 216</p><p id="ref_9">9. Seidel EA, Koenig S, Polis MA "A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet." AIDS 7 (1993): 941-5</p><p id="ref_10">10. Deray G, Katlama C, Dohin E "Prevention of foscarnet nephrotoxicity." Ann Intern Med 113 (1990): 332</p><p id="ref_11">11. Ringden O, Lonnqvist B, Paulin T, et al "Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients." J Antimicrob Chemother 17 (1986): 373-87</p><p id="ref_12">12. Jacobson MA "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr 5 (1992): s11-7</p><p id="ref_13">13. Navarro JF, Quereda C, Moreno A, Quereda C "Renal tubular acidosis following treatment with foscarnet." AIDS 9 (1995): 1389-90</p><p id="ref_14">14. Chrisp P, Clissold SP "Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis." Drugs 41 (1991): 104-29</p><p id="ref_15">15. Wald A "New therapies and prevention strategies for genital herpes." Clin Infect Dis 28 (1999): s4-13</p><p id="ref_16">16. Szczech LA "Hypertension and medication-related renal dysfunction in the HIV-infected patient." Semin Nephrol 21 (2001): 386-93</p><p id="ref_17">17. SOCA Reseach Group, et al "Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis." N Engl J Med 326 (1992): 213-20</p><p id="ref_18">18. Goldfarb DS, Coe FL "Foscarnet crystal deposition and renal failure." Am J Kidney Dis 32 (1998): 519-20</p><p id="ref_19">19. Izzedine H,  Launay-Vacher V,  Deray G "Antiviral drug-induced nephrotoxicity." Am J Kidney Dis 45 (2005): 804-17</p><p id="ref_20">20. Blanshard C "Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet." J Acquir Immune Defic Syndr 5 (1992): s25-8</p><p id="ref_21">21. Cacoub P, Deray G, Baumelou A, et al "Acute renal failure induced by foscarnet: 4 cases." Clin Nephrol 29 (1988): 315-8</p><p id="ref_22">22. Deray G, Martinez F, Katlama C, et al "Foscarnet nephrotoxicity: mechanism, incidence and prevention." Am J Nephrol 9 (1989): 316-21</p><p id="ref_23">23. MauriceEstepa L, Daudon M, Katlama C, Jouanneau C, Sazdovitch V, Lacour B, Beaufils H "Identification of crystals in kidneys of AIDS patients treated with foscarnet." Am J Kidney Dis 32 (1998): 392-400</p><p id="ref_24">24. Willocks L, Brettle R "Foscarnet and pancytopenia." J Antimicrob Chemother 29 (1992): 232</p><p id="ref_25">25. Palestine AG, Polis MA, De Smet MD, et al "A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS." Ann Intern Med 115 (1991): 665-73</p><p id="ref_26">26. Roling J,  Schmid H,  Fischereder M,  Draenert R,  Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95</p><p id="ref_27">27. Conn J, Colman P, Brown G, Street A, Bate K "Nephrogenic diabetes insipidus associated with foscarnet - a case report." J Antimicrob Chemother 37 (1996): 1179-81</p><p id="ref_28">28. Jacobson MA, Gambertoglio JG, Aweeka FT, et al "Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism." J Clin Endocrinol Metab 72 (1991): 1130-5</p><p id="ref_29">29. Gearhart MO, Sorg TB "Foscarnet-induced severe hypomagnesemia and other electrolyte disorders." Ann Pharmacother 27 (1993): 285-9</p><p id="ref_30">30. Gayet S, Ville E, Durand JM, Mars ME, Morange S, Kaplanski G, Gallais H, Soubeyrand J "Foscarnet-induced hypercalcaema in AIDS." AIDS 11 (1997): 1068-70</p><p id="ref_31">31. Holbrook J, Jabs D, Jacobson M, Mendez P, Min Y, Murphy R "Foscarnet-related abnormalities in serum creatinine, calcium, and magnesium in patients with CMV retinitis. The SOCA Research Group." Int Conf AIDS 9 (1993): 361</p><p id="ref_32">32. Guillaume MP, Karmali R, Bergmann P, Cogan E "Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS." Clin Infect Dis 25 (1997): 932-3</p><p id="ref_33">33. Barba R, GomezRodrigo J, Marco J, Espejo M, Mena D "Transient foscarnet-induced hypercalcaemia." AIDS 12 (1998): 1930-1</p><p id="ref_34">34. Malin A, Miller RF "Foscarnet-induced hypokalaemia." J Infect 25 (1992): 329-30</p><p id="ref_35">35. Saint-Marc T, Fournier F, Touraine J-L, Marneff E "Uvula and oesophageal ulcerations with foscarnet." Lancet 340 (1992): 970-1</p><p id="ref_36">36. Roos TC, Albrecht H "Foscarnet-associated eosinophilic folliculitis in a patient with AIDS." J Am Acad Dermatol 44 (2001): 546-7</p><p id="ref_37">37. Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994): 869-72</p><p id="ref_38">38. Lor E, Liu YQ "Neurologic sequelae associated with foscarnet therapy." Ann Pharmacother 28 (1994): 1035-7</p><p id="ref_39">39. Fegeuex S, Salmon D, Picard C, et al "Penile ulcerations with foscarnet." Lancet 335 (1990): 547-8</p><p id="ref_40">40. Lacey HB, Ness A, Mandal BK "Vulval ulceration associated with foscarnet." Genitourin Med 68 (1992): 182</p><p id="ref_41">41. Gilquin J, Weiss L, Kazatchkine MD "Genital and oral erosions induced by foscarnet." Lancet 335 (1990): 287</p><p id="ref_42">42. Moyle G, Barton S, Gazzard BG "Penile ulceration with foscarnet therapy." AIDS 7 (1993): 140-1</p><p id="ref_43">43. Green ST, Nathwani D, Goldberg DJ, Mack DJ, Kennedy DH "Generalised cutaneous rash associated with foscarnet usage in AIDS." J Infect 21 (1990): 227-8</p><p id="ref_44">44. Caumes E, Gatineau M, Bricaire F, Dohin E, Katlama C, Gentilini M "Foscarnet-induced vulvar erosion." J Am Acad Dermatol 28 (1993): 799</p><p id="ref_45">45. Evans LM, Grossman ME "Foscarnet-induced penile ulcer." J Am Acad Dermatol 27 (1992): 124-6</p><p id="ref_46">46. Sohl Akerlund A, Keisu M, Lernestedt JO, Sandberg M "Penile ulcerations in connection with foscarnet therapy. Clinical picture and incidence." Int Conf AIDS 9 (1993): 358</p><p id="ref_47">47. Connolly GM, Gazzard BG, Hawkins DA "Fixed drug eruption due to foscarnet." Genitourin Med 66 (1990): 97-8</p><p id="ref_48">48. Brown DL, Sather S, Cheitlin MD "Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient." Am Heart J 125 (1993): 1439-41</p></div>
<div class="more-resources" id="moreResources">
<h2>More about foscarnet</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antivirals</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Foscarnet Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Foscavir</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>CMV Gastroenteritis</li>
<li>CMV Retinitis</li>
<li>Herpes Simplex, Mucocutaneous/Immunocompromised Host</li>
<li>Varicella-Zoster</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to foscarnet: intravenous solution</i></p><h3>General</h3><p>Renal impairment was the major toxicity of this drug.  The most frequent side effects reported during clinical trials included fever, nausea, anemia, diarrhea, abnormal renal function, vomiting, headache, and seizures.  Severe side effects included death, abnormal renal function, bone marrow suppression, anemia, and seizures.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Renal impairment (up to 33%), abnormal renal function (up to 27%), increased serum creatinine</p><p><b>Common</b> (1% to 10%): Altered renal function, decreased CrCl, increased BUN, acute renal failure, renal pain</p><p><b>Uncommon</b> (0.1% to 1%): Renal tubular disorder</p><p><b>Frequency not reported</b>: Increased serum creatinine to greater than 2.9 mg/dL, acute tubular necrosis, drug crystals in renal tubules and capillaries, nephrotoxicity</p><p><b>Postmarketing reports</b>: Nephrogenic diabetes insipidus, renal tubular acidosis, renal calculus, renal tubular necrosis, crystal-induced nephropathy<sup>[Ref]</sup></p><p>About 33% of AIDS patients with CMV retinitis who used this drug without adequate hydration reported significant renal impairment (serum creatinine at least 2 mg/dL).  When administered with 1000 mL of normal saline or 5% dextrose solution, the incidence decreased to 12%.</p><p></p><p>Renal side effects were due to acute tubular necrosis, possibly from deposition of drug crystals in the renal tubules and capillaries.  The development of nephrotoxicity was most common during the third week of therapy in 1 study.</p><p></p><p>Nephrotoxicity was reversible in patients with previously adequate renal function.  Hydration with 2.5 liters of normal saline per day beginning the day before therapy decreased the incidence of nephrotoxicity.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Serum electrolyte changes, mineral and electrolyte imbalances, hypokalemia (up to 48%), hypocalcemia (up to 30%), hypomagnesemia (up to 30%), hypophosphatemia (up to 26%), decreased appetite, anorexia</p><p><b>Common</b> (1% to 10%): Hyperphosphatemia, abnormal albumin to globulin ratio, hyponatremia, decreased weight, increased alkaline phosphatase, increased lactate dehydrogenase, acidosis, cachexia, thirst</p><p><b>Uncommon</b> (0.1% to 1%): Dehydration, hypoproteinemia</p><p><b>Frequency not reported</b>: Hypercalcemia., decreased serum ionized calcium levels<sup>[Ref]</sup></p><p>The higher percentages of serum electrolyte changes (including hypokalemia, hypocalcemia, hypomagnesemia, hypophosphatemia, hyperphosphatemia) were reported in patients receiving hydration.</p><p></p><p>Serum ionized calcium levels have been shown to decrease acutely in a dose-dependent manner after an infusion of this drug.  Total calcium and phosphate levels were not significantly affected.  This drug is believed to complex with ionized calcium.</p><p></p><p>More severe metabolic abnormalities have resulted in tremors, twitches, arrhythmias, paresthesias, and seizures.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 47%), diarrhea (up to 30%), vomiting (up to 26%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, constipation, dysphagia, dyspepsia, rectal hemorrhage, dry mouth, melena, flatulence, ulcerative stomatitis, pancreatitis</p><p><b>Uncommon</b> (0.1% to 1%): Increased amylase</p><p><b>Frequency not reported</b>: Uvula ulceration</p><p><b>Postmarketing reports</b>: Esophageal ulceration<sup>[Ref]</sup></p><h3>Other</h3><p>In controlled trials, death was specifically attributed to this drug in 1 case; however, other drug complications (e.g., renal impairment, electrolyte abnormalities, seizures) may have contributed to patient deaths.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Fever/pyrexia (up to 65%), death (up to 14%), fatigue, asthenia, chills</p><p><b>Common</b> (1% to 10%): Rigors, malaise, pain, infection, sepsis, chest pain, edema, influenza-like symptoms, bacterial infections, moniliasis, fungal infections, abscess, facial edema</p><p><b>Frequency not reported</b>: Catheterization-related infection, hospitalization, drug accumulation in teeth and bones<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (up to 33%), granulocytopenia (up to 17%), decreased hemoglobin</p><p><b>Common</b> (1% to 10%): Marrow suppression, neutropenia, leukopenia, thrombocytopenia, platelet abnormalities, thrombosis, white blood cell abnormalities, lymphadenopathy</p><p><b>Uncommon</b> (0.1% to 1%): Pancytopenia</p><p><b>Frequency not reported</b>: Decreased absolute neutrophil count (ANC) to less than 0.5 x 10(9)/L, hemoglobin less than 7 g/dL<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 26%), paresthesia, dizziness</p><p><b>Common</b> (1% to 10%): Seizures/convulsion (including grand mal seizures), involuntary muscle contractions, hypoesthesia, neuropathy, tremor, ataxia, dementia, stupor, generalized spasms, sensory disturbances, meningitis, aphasia, abnormal coordination, leg cramps, electroencephalogram abnormalities, amnesia, somnolence, taste perversions, peripheral neuropathy</p><p><b>Uncommon</b> (0.1% to 1%): Coma, other neurologic complications</p><p><b>Postmarketing reports</b>: Encephalopathy<sup>[Ref]</sup></p><p>Risk factors for drug-related seizures included underlying central nervous system conditions predisposing patients to seizures, impaired baseline renal function, and low total serum calcium.  The rate of seizures did not increase with duration of therapy.  At least 3 cases were reported with overdoses of this drug.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash</p><p><b>Common</b> (1% to 10%): Increased sweating, pruritus, skin ulceration, seborrhea, erythematous rash, maculopapular rash, skin discoloration</p><p><b>Frequency not reported</b>: Eosinophilic folliculitis</p><p><b>Postmarketing reports</b>: Vesiculobullous eruptions, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome<sup>[Ref]</sup></p><p>When toxic epidermal necrolysis or Stevens-Johnson syndrome was reported, patients were usually taking other agents associated with those reactions.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site pain, injection site inflammation<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, palpitations, ECG abnormalities, sinus tachycardia, first degree atrioventricular block, nonspecific ST-T segment changes, hypotension, flushing, cerebrovascular disorder, thrombophlebitis</p><p><b>Uncommon</b> (0.1% to 1%): Cardiac arrest, other cardiovascular complications</p><p><b>Frequency not reported</b>: Reversible cardiac dysfunction, increased heart rate</p><p><b>Postmarketing reports</b>: Ventricular arrhythmia, QT interval prolongation<sup>[Ref]</sup></p><p>Reversible cardiac dysfunction was reported in a patient using this drug, who experienced shortness of breath, increased heart rate, and pulmonary edema, which reoccurred upon rechallenge.  Serum electrolytes were within normal limits.</p><p></p><p>Thrombophlebitis in peripheral veins has been reported after infusion of undiluted drug solution.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal hepatic function, increased ALT/SGPT, increased AST/SGOT, increased GGT<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, myalgia</p><p><b>Uncommon</b> (0.1% to 1%): Increased creatine phosphokinase</p><p><b>Frequency not reported</b>: Twitches</p><p><b>Postmarketing reports</b>: Muscle disorders including myopathy, myositis, muscle weakness, rhabdomyolysis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Lymphoma-like disorder, sarcoma<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Coughing, dyspnea, pneumonia, sinusitis, pharyngitis, rhinitis, respiratory disorders, respiratory insufficiency, pulmonary infiltration, stridor, pneumothorax, hemoptysis, bronchospasm</p><p><b>Frequency not reported</b>: Pulmonary edema<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, confusion, anxiety, insomnia, nervousness, agitation, aggression, hallucination</p><p><b>Postmarketing reports</b>: Mental status changes<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Vision abnormalities, eye abnormalities, eye pain, conjunctivitis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>High levels of this drug are excreted in the urine and may be associated with significant irritation and ulceration in the genital area, especially after prolonged therapy.</p><p></p><p>Penile ulcerations have been reported to occur after a median of 11 days of induction therapy and 30 days of maintenance therapy, and healed within 6 days of drug discontinuation.  Ulceration has been reported more often in uncircumcised patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Albuminuria, dysuria, polyuria, urethral disorder, urinary retention, urinary tract infections, nocturia, genital discomfort/irritation and ulceration</p><p><b>Uncommon</b> (0.1% to 1%): Hematuria</p><p><b>Frequency not reported</b>: Local irritation/ulceration of penile epithelium, vulvovaginal ulceration, penile ulceration, vulvar erosion<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Syndrome of inappropriate antidiuretic hormone secretion</p><p><b>Postmarketing reports</b>: Diabetes insipidus</p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Takami A,  Mochizuki K,  Ito S, et al. "Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation." Transplant Proc 39 (2007): 237-9</p><p id="ref_4">4. "Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA. </p><p id="ref_5">5. Farese RV Jr, Schambelan M, Hollander H, et al "Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis." Ann Intern Med 112 (1990): 955-6</p><p id="ref_6">6. Zanetta G, MauriceEstepa L, Mousson C, Justrabo E, Daudon M, Rifle G, Tanter Y "Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation." Transplantation 67 (1999): 1376-8</p><p id="ref_7">7. Navarro JF, Quereda C, Quereda C, Gallego N, Antela A, Mora C, Ortuno J "Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy." Am J Kidney Dis 27 (1996): 431-4</p><p id="ref_8">8. Deray G, Le Hoang P, Soubrie C, et al "Foscarnet-induced acute renal failure and effectiveness of haemodialysis." Lancet 2 (1987): 216</p><p id="ref_9">9. Seidel EA, Koenig S, Polis MA "A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet." AIDS 7 (1993): 941-5</p><p id="ref_10">10. Deray G, Katlama C, Dohin E "Prevention of foscarnet nephrotoxicity." Ann Intern Med 113 (1990): 332</p><p id="ref_11">11. Ringden O, Lonnqvist B, Paulin T, et al "Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients." J Antimicrob Chemother 17 (1986): 373-87</p><p id="ref_12">12. Jacobson MA "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr 5 (1992): s11-7</p><p id="ref_13">13. Navarro JF, Quereda C, Moreno A, Quereda C "Renal tubular acidosis following treatment with foscarnet." AIDS 9 (1995): 1389-90</p><p id="ref_14">14. Chrisp P, Clissold SP "Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis." Drugs 41 (1991): 104-29</p><p id="ref_15">15. Wald A "New therapies and prevention strategies for genital herpes." Clin Infect Dis 28 (1999): s4-13</p><p id="ref_16">16. Szczech LA "Hypertension and medication-related renal dysfunction in the HIV-infected patient." Semin Nephrol 21 (2001): 386-93</p><p id="ref_17">17. SOCA Reseach Group, et al "Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis." N Engl J Med 326 (1992): 213-20</p><p id="ref_18">18. Goldfarb DS, Coe FL "Foscarnet crystal deposition and renal failure." Am J Kidney Dis 32 (1998): 519-20</p><p id="ref_19">19. Izzedine H,  Launay-Vacher V,  Deray G "Antiviral drug-induced nephrotoxicity." Am J Kidney Dis 45 (2005): 804-17</p><p id="ref_20">20. Blanshard C "Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet." J Acquir Immune Defic Syndr 5 (1992): s25-8</p><p id="ref_21">21. Cacoub P, Deray G, Baumelou A, et al "Acute renal failure induced by foscarnet: 4 cases." Clin Nephrol 29 (1988): 315-8</p><p id="ref_22">22. Deray G, Martinez F, Katlama C, et al "Foscarnet nephrotoxicity: mechanism, incidence and prevention." Am J Nephrol 9 (1989): 316-21</p><p id="ref_23">23. MauriceEstepa L, Daudon M, Katlama C, Jouanneau C, Sazdovitch V, Lacour B, Beaufils H "Identification of crystals in kidneys of AIDS patients treated with foscarnet." Am J Kidney Dis 32 (1998): 392-400</p><p id="ref_24">24. Willocks L, Brettle R "Foscarnet and pancytopenia." J Antimicrob Chemother 29 (1992): 232</p><p id="ref_25">25. Palestine AG, Polis MA, De Smet MD, et al "A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS." Ann Intern Med 115 (1991): 665-73</p><p id="ref_26">26. Roling J,  Schmid H,  Fischereder M,  Draenert R,  Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95</p><p id="ref_27">27. Conn J, Colman P, Brown G, Street A, Bate K "Nephrogenic diabetes insipidus associated with foscarnet - a case report." J Antimicrob Chemother 37 (1996): 1179-81</p><p id="ref_28">28. Jacobson MA, Gambertoglio JG, Aweeka FT, et al "Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism." J Clin Endocrinol Metab 72 (1991): 1130-5</p><p id="ref_29">29. Gearhart MO, Sorg TB "Foscarnet-induced severe hypomagnesemia and other electrolyte disorders." Ann Pharmacother 27 (1993): 285-9</p><p id="ref_30">30. Gayet S, Ville E, Durand JM, Mars ME, Morange S, Kaplanski G, Gallais H, Soubeyrand J "Foscarnet-induced hypercalcaema in AIDS." AIDS 11 (1997): 1068-70</p><p id="ref_31">31. Holbrook J, Jabs D, Jacobson M, Mendez P, Min Y, Murphy R "Foscarnet-related abnormalities in serum creatinine, calcium, and magnesium in patients with CMV retinitis. The SOCA Research Group." Int Conf AIDS 9 (1993): 361</p><p id="ref_32">32. Guillaume MP, Karmali R, Bergmann P, Cogan E "Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS." Clin Infect Dis 25 (1997): 932-3</p><p id="ref_33">33. Barba R, GomezRodrigo J, Marco J, Espejo M, Mena D "Transient foscarnet-induced hypercalcaemia." AIDS 12 (1998): 1930-1</p><p id="ref_34">34. Malin A, Miller RF "Foscarnet-induced hypokalaemia." J Infect 25 (1992): 329-30</p><p id="ref_35">35. Saint-Marc T, Fournier F, Touraine J-L, Marneff E "Uvula and oesophageal ulcerations with foscarnet." Lancet 340 (1992): 970-1</p><p id="ref_36">36. Roos TC, Albrecht H "Foscarnet-associated eosinophilic folliculitis in a patient with AIDS." J Am Acad Dermatol 44 (2001): 546-7</p><p id="ref_37">37. Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994): 869-72</p><p id="ref_38">38. Lor E, Liu YQ "Neurologic sequelae associated with foscarnet therapy." Ann Pharmacother 28 (1994): 1035-7</p><p id="ref_39">39. Fegeuex S, Salmon D, Picard C, et al "Penile ulcerations with foscarnet." Lancet 335 (1990): 547-8</p><p id="ref_40">40. Lacey HB, Ness A, Mandal BK "Vulval ulceration associated with foscarnet." Genitourin Med 68 (1992): 182</p><p id="ref_41">41. Gilquin J, Weiss L, Kazatchkine MD "Genital and oral erosions induced by foscarnet." Lancet 335 (1990): 287</p><p id="ref_42">42. Moyle G, Barton S, Gazzard BG "Penile ulceration with foscarnet therapy." AIDS 7 (1993): 140-1</p><p id="ref_43">43. Green ST, Nathwani D, Goldberg DJ, Mack DJ, Kennedy DH "Generalised cutaneous rash associated with foscarnet usage in AIDS." J Infect 21 (1990): 227-8</p><p id="ref_44">44. Caumes E, Gatineau M, Bricaire F, Dohin E, Katlama C, Gentilini M "Foscarnet-induced vulvar erosion." J Am Acad Dermatol 28 (1993): 799</p><p id="ref_45">45. Evans LM, Grossman ME "Foscarnet-induced penile ulcer." J Am Acad Dermatol 27 (1992): 124-6</p><p id="ref_46">46. Sohl Akerlund A, Keisu M, Lernestedt JO, Sandberg M "Penile ulcerations in connection with foscarnet therapy. Clinical picture and incidence." Int Conf AIDS 9 (1993): 358</p><p id="ref_47">47. Connolly GM, Gazzard BG, Hawkins DA "Fixed drug eruption due to foscarnet." Genitourin Med 66 (1990): 97-8</p><p id="ref_48">48. Brown DL, Sather S, Cheitlin MD "Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient." Am Heart J 125 (1993): 1439-41</p><h2>More about foscarnet</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antivirals</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Foscarnet Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>CMV Gastroenteritis</li>
<li>CMV Retinitis</li>
<li>Herpes Simplex, Mucocutaneous/Immunocompromised Host</li>
<li>Varicella-Zoster</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>